Status:
COMPLETED
Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain
Lead Sponsor:
Bayer
Collaborating Sponsors:
Janssen Research & Development, LLC
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
Depict demographic and clinical features of patients with atrial fibrillation treated with rivaroxaban to prevent stroke and pulmonary embolism in routine clinical practice
Eligibility Criteria
Inclusion
- Patients ≥ 18 years
- Patients with atrial fibrillation
- Patients in treatment with rivaroxaban for stroke prevention in atrial fibrillation at least 3 months previous to inclusion period in study
Exclusion
- Patients in treatment after start of study
- Patients treated with other anticoagulant treatment
Key Trial Info
Start Date :
October 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
2251 Patients enrolled
Trial Details
Trial ID
NCT02262676
Start Date
October 1 2014
End Date
May 1 2015
Last Update
January 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Spain